Compare ALCO & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | PLYX |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 262.3M |
| IPO Year | 1994 | N/A |
| Metric | ALCO | PLYX |
|---|---|---|
| Price | $37.90 | $5.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 25.3K | ★ 1.9M |
| Earning Date | 02-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.61 | $2.20 |
| 52 Week High | $43.20 | $8.15 |
| Indicator | ALCO | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 51.82 |
| Support Level | $37.14 | $2.44 |
| Resistance Level | $38.40 | $7.43 |
| Average True Range (ATR) | 1.41 | 1.11 |
| MACD | -0.25 | 0.26 |
| Stochastic Oscillator | 11.51 | 57.76 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.